Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company dedicated to developing transformative medicines for serious diseases with a focus on specialty markets. The company leverages a serial innovation strategy to discover and commercialize therapies that address the underlying causes of diseases such as cystic fibrosis, sickle cell disease, and acute pain. Their approach combines deep human biology insights with advanced therapeutic modalities to deliver first-in-class and best-in-class treatments.
Financials
Based on Q1 2026 filing
Revenue
View metricGross Profit
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Cystic Fibrosis (CF)
primaryA portfolio of CFTR modulators designed to treat the underlying genetic cause of cystic fibrosis by improving protein function. These therapies serve the vast majority of the global CF patient population across major markets.
ALYFTREK, TRIKAFTA, KAFTRIO, SYMDEKO, SYMKEVI, ORKAMBI, KALYDECO
Specialty pharmacies, Healthcare providers, Hospitals
Hematology and Pain Management
majorRecently approved therapies and late-stage programs targeting sickle cell disease, transfusion-dependent beta thalassemia, and acute pain management using non-opioid mechanisms.
CASGEVY, SUZETRIGINE
Specialty hospitals, Pain management clinics, Infusion centers
Specialty Pipeline Programs
minorResearch and development efforts focused on high-unmet-need areas including kidney diseases, type 1 diabetes, and rare genetic disorders.
povetacicept, inaxaplin, zimislecel
Clinical trial participants, Research institutions
Segment Financials
ALYFTREK — Royalty burden, percentage
View metricPharmaceuticals — Development expenses
View metricPharmaceuticals — Research expenses
View metricPharmaceuticals — Selling and other commercial expenses
View metricBusiness Overview
Competitive Position
Vertex is the dominant leader in the cystic fibrosis market and a pioneer in CRISPR-based gene editing and non-opioid pain treatments.
Geographies
United States, Europe, Australia, Canada
Customer Segments
Patients with rare diseases, Specialized healthcare systems, Government health programs
Upstream Dependencies
Specialized raw material suppliers, Contract manufacturing organizations, Academic research institutions, Genetic sequencing providers
Downstream Customers
Specialty drug distributors, Public and private insurers, Specialized medical centers
Competitors & Partners
Partners
Subsidiaries
Alpine Immune Sciences
Acquired entity providing the povetacicept program
Vertex Pharmaceuticals FAQ
Common questions about Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company dedicated to developing transformative medicines for serious diseases with a focus on specialty markets. The company leverages a serial innovation strategy to discover and commercialize therapies that address the underlying causes of diseases such as cystic fibrosis, sickle cell disease, and acute pain. Their approach combines deep human biology insights with advanced therapeutic modalities to deliver first-in-class and best-in-class treatments.
Vertex Pharmaceuticals (VRTX) has a market capitalization of $110.28B and trades on NASDAQ.
Vertex Pharmaceuticals generated $12.2B in trailing twelve-month revenue with net income of $4.3B, representing a net margin of 35.5%. Gross margin stands at 86.2%, with free cash flow of $3.7B. These figures are based on the Q1 2026 filing.
Vertex Pharmaceuticals's key competitors include AbbVie, Bristol-Myers Squibb Co., Merck & Co., Inc., and others. These companies compete in similar markets and product categories.
Vertex Pharmaceuticals has approximately 5,400 employees.